Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the ...

An experimental Boehringer Ingelheim drug achieved “unprecedented” benefits in patients with an advanced form of lung cancer ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very ...

The trial previously reported a 71% objective response rate (ORR) – indicating tumor shrinkage – in 75 patients from the first cohort, but newly presented data include a median duration of response ...

They may recommend treatments to help manage your symptoms ... One clinical trial of Opdivo involved adults with squamous non-small cell lung cancer (NSCLC). Researchers found that people with ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Williams, 70, has to pay nearly $180,000 for his cancer therapy, of which more than $25,000 will go on GST. “It’s a tax on ...